We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

17 hedge funds and large institutions have $2.91M invested in Moleculin Biotech in 2020 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 0 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

23% less funds holding

Funds holding: 22 → 17 (-5)

32% less capital invested

Capital invested by funds: $4.26M → $2.91M (-$1.35M)

63% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 8

Holders
17
Holders Change
-5
Holders Change %
-22.73%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
7
Reduced
–
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$194K
2
TSS
Two Sigma Securities
New York
+$57.9K
3
RJFSA
Raymond James Financial Services Advisors
Florida
+$39.2K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$37.5K
5
Citadel Advisors
Citadel Advisors
Florida
+$11.9K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$137K
2
Millennium Management
Millennium Management
New York
-$88K
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$65K
4
Morgan Stanley
Morgan Stanley
New York
-$32K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$16K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.62M +$37.5K +22 +2%
Renaissance Technologies
2
Renaissance Technologies
New York
$770K +$194K +114 +25%
Truist Financial
3
Truist Financial
North Carolina
$85K – – –
BlackRock
4
BlackRock
New York
$85K +$1.7K +1 +2%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$77K – – –
WIC
6
Whitegate Investment Counselors
New Hampshire
$62K – – –
TSS
7
Two Sigma Securities
New York
$55K +$57.9K +34 +567%
RJFSA
8
Raymond James Financial Services Advisors
Florida
$44K +$39.2K +23 +256%
Northern Trust
9
Northern Trust
Illinois
$40K – – –
Citadel Advisors
10
Citadel Advisors
Florida
$22K +$11.9K +7 +78%
UBS Group
11
UBS Group
Switzerland
$21K +$10.2K +6 +67%
Victory Capital Management
12
Victory Capital Management
Texas
$10K +$11.9K +7 New
HWA
13
HCR Wealth Advisors
California
$9K +$11.9K +7 New
PFGIA
14
Patriot Financial Group Insurance Agency
Massachusetts
$2K – – –
OPS
15
Orion Portfolio Solutions
Nebraska
$2K +$1.7K +1 New
APA
16
American Portfolios Advisors
New York
$1.22K – – –
Carson Wealth (CWM LLC)
17
Carson Wealth (CWM LLC)
Nebraska
$1K – – –
GRP
18
Global Retirement Partners
California
$1K – – –
PWMG
19
Prestige Wealth Management Group
New Jersey
$1K – – –
Royal Bank of Canada
20
Royal Bank of Canada
Ontario, Canada
$1K – – –
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
– -$137K -67 Closed
Millennium Management
22
Millennium Management
New York
– -$88K -43 Closed
Bank of New York Mellon
23
Bank of New York Mellon
New York
– -$65K -31 Closed
Morgan Stanley
24
Morgan Stanley
New York
– -$32K -16 Closed
Dimensional Fund Advisors
25
Dimensional Fund Advisors
Texas
– -$16K -8 Closed
1
2

MBRX Hedge Fund Activity: Q1 2020 in Review

17 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q1 2020, worth a combined $2.91M — down 32% from $4.26M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of MBRX and 3 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 7 added.

The largest buyer was Renaissance Technologies, adding an estimated $194K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $137K sold.

  • 17 institutional investors held Moleculin Biotech (MBRX) as of Q1 2020, down from 22 in Q4 2019.
  • Funds reported $2.91M of Moleculin Biotech stock for Q1 2020, down 32% quarter-over-quarter.
  • 3 funds opened new Moleculin Biotech positions in Q1 2020 and 8 closed out, a net change of -5 holders.
  • The largest Moleculin Biotech buyer in Q1 2020 was Renaissance Technologies, an estimated $194K added.
  • The largest Moleculin Biotech seller in Q1 2020 was Susquehanna International Group, an estimated $137K sold.

Based on aggregated 13F filings for Q1 2020.